🇺🇸

Distress Insolvency

US SEC Filing Intelligence · 186 digests

· daily

US Corporate Distress Financial Stress SEC Filings — October 09, 2026

All five filings in this stream are distress-related, centered on US exchange listing deficiencies rather than bankruptcy filings or going-concern opinions. The common thread is Nasdaq and NYSE/NYSE American continued-listing enforcement: three companies face sub-$1 bid-price or equity-related deficiencies (Streamex, Accendra Health), and three face governance or filing-compliance failures (Better Home & Finance, IT Tech Packaging), with Alaunos already at the delisting-hearing stage. Because the enriched period-over-period, insider, capital-allocation and forward-looking fields were not populated in these filings, quantitative trend comparisons are not available; the analysis therefore rests on the explicit deadlines, notice dates and materiality ratings disclosed. The most critical development is Alaunos Therapeutics (materiality 8/10), where the October 5, 2026 delisting notice for sub-$2.5M stockholders' equity is now proceeding to a Hearings Panel with a strategic-alternatives process that carries no assured outcome. IT Tech Packaging (8/10) and Better Home & Finance (7/10) also carry near-term enforcement risk, while Streamex and Accendra have the longest cure windows (to April 2027 and roughly April 2027 respectively). Portfolio-level, the pattern is distress manifesting as exchange compliance pressure well ahead of any insolvency event.

5 high priority 5 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 07, 2026

This digest covers a single filing from Greenlane Holdings, Inc., which falls squarely within the Bankruptcy & Insolvency stream. The company’s 8-K reveals that four subsidiaries made assignments for the benefit of creditors (ABCs) under Florida law, effectively transferring substantially all assets to an assignee for liquidation. This action results in deconsolidation, removing $594,573 in assets and $3,754,180 in liabilities from the balance sheet, though liabilities are not discharged. Pro forma financials show a dramatic 95% revenue decline from $4.355M to $225,000 for FY2025, while net loss improves from $85.580M to $48.117M due to the removal of subsidiary losses. Critically, the parent company received no consideration for the assignments and continues to report significant operating losses and unrealized losses on digital assets, indicating a deeply distressed financial position. The negative sentiment and high materiality (9/10) underscore a severe solvency crisis with no apparent turnaround path, making this a high-risk event for stakeholders.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 06, 2026

The October 6, 2026, corporate distress landscape is dominated by two Nasdaq compliance failures (FibroGen/Kyntra Bio and Virtuix Holdings), both receiving Staff Determinations on the same day (Sept 30, 2026) for failing to meet minimum market value and alternative financial standards. This clustering suggests a potential tightening of Nasdaq enforcement or a broader market-cap erosion among small-cap issuers. International Bancshares Corporation's voluntary delisting to the Texas Stock Exchange is a non-distress event and is excluded from further analysis. Neither distressed company provided period-over-period financial comparisons, forward guidance, or insider trading data in their 8-K filings, limiting quantitative trend analysis. The key actionable insight is the 180-day compliance window for both firms, creating a binary catalyst timeline. The lack of insider buying or capital allocation disclosures in these filings is itself a bearish signal, suggesting management is not signaling confidence through open-market purchases.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 05, 2026

The four filings reveal stark distress across US-listed companies, with two imminent delistings and one bankruptcy filing on a single day. ESS Tech faces a second NYSE delisting for failing to maintain a $15 million market cap, forcing a move to OTC markets and severely reducing liquidity. Purple Innovation received a Nasdaq non-compliance notice for failing the $15 million MVPHS threshold, with a compliance deadline that appears to contain a typo, adding uncertainty. Leslie's filed for Chapter 11 bankruptcy on September 30, 2026, securing a $90 million DIP facility to fund operations. CECO Environmental's voluntary switch from Nasdaq to the Texas Stock Exchange is the only non-distressed event, though it signals a strategic shift. No insider trading or forward-looking guidance was disclosed in any filing, limiting fundamental trend analysis. The cluster of events on September 30 and October 2, 2026, suggests macro pressures from rising rates or sector-specific headwinds are accelerating distress.

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — October 05, 2026

Leslie's, Inc. filed for Chapter 11 bankruptcy on September 30, 2026, marking a critical inflection point for the company and the broader pool retail sector. The filing reveals a severe liquidity crisis, addressed through a $90 million debtor-in-possession (DIP) facility to fund operations during restructuring. The absence of period-over-period financial data in the filing underscores the urgency and opacity of the situation, with the company's future hinging on successful court-approved restructuring. This event signals potential distress among discretionary consumer goods retailers, particularly those with high debt loads and seasonal cash flow patterns. The DIP facility's terms, including covenants and milestones, will be key indicators of the company's restructuring trajectory. Investors should monitor the bankruptcy proceedings for asset sale opportunities and potential equity wipeout scenarios.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 02, 2026

All 8 filings in this digest signal acute distress across US-listed micro-cap companies, with 8/8 receiving delisting or deficiency notices from Nasdaq or NYSE American within a single week (September 28-October 1, 2026). The dominant theme is a liquidity crisis: 6 companies failed the $1.00 minimum bid price rule, one failed the $35M MVLS requirement, and one was delisted for low selling price. Notably, 3 companies (Amaze, Direct Digital, Healthcare Triangle) face imminent trading suspensions, with Healthcare Triangle ineligible for standard cure periods due to two reverse splits totaling 1-for-14,940—a hallmark of chronic price decay. The cluster of identical compliance deadlines (March 29, 2027) suggests a systemic wave of micro-cap distress, likely driven by sustained selling pressure and weak fundamentals. No period-over-period financial data or insider activity was disclosed in these filings, limiting quantitative trend analysis, but the absence of any bullish signals underscores the severity. The most critical near-term catalyst is Healthcare Triangle's October 8 appeal deadline, which will determine whether it faces immediate suspension. Investors should treat these as high-risk situations with limited upside, though potential reverse-split-driven compliance and OTC market transitions create speculative trading opportunities.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — October 01, 2026

This digest covers six US SEC filings from October 1, 2026, all within the corporate distress and bankruptcy stream. The dominant theme is a wave of Nasdaq and NYSE delisting actions, with three companies (Lantern Pharma, Gaxos.ai, Getty Images) receiving non-compliance or delisting notices due to market value, bid price, or abnormally low selling price failures. Getty Images has already been suspended and moved to the OTC market, while Lantern Pharma and Gaxos.ai have 180-day cure periods. A fourth company, SKYX Platforms, fell out of compliance due to a board member's death, triggering governance rule violations. NSTS Bancorp completed a cash merger and was voluntarily delisted, representing a clean exit. Nextdoor voluntarily transferred its listing from NYSE to Nasdaq, a non-distressed move. Period-over-period data was limited in these filings, but the concentration of delisting events signals heightened distress in small-cap and micro-cap equities, particularly in the AI and biotech sectors. Insider activity was absent across all filings, and no forward-looking guidance or capital allocation changes were disclosed, limiting trend analysis but amplifying the urgency of the compliance deadlines.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 30, 2026

The four filings collectively paint a stark picture of distress across US-listed companies, with all four facing delisting or bankruptcy events in September 2026. Notably, three of the four (ESS Tech, Outlook Therapeutics, Petros Pharmaceuticals) are micro-cap or small-cap companies grappling with NYSE/Nasdaq listing standards, while the fourth (Leslie's) is a larger retailer executing a prearranged Chapter 11 restructuring. Period-over-period data, where available, shows no revenue growth or margin improvements, and all filings carry negative sentiment with materiality scores of 8-10/10. The most critical development is Leslie's bankruptcy, which eliminates ~$685M (90%) of funded debt and secures $150M in new capital, signaling a potential restructuring opportunity. The sector themes indicate a bifurcation: smaller biotech/industrial companies face liquidity-driven delisting risks, while larger consumer discretionary names use Chapter 11 to deleverage and streamline operations. Insider activity is notably absent across all filings, suggesting management teams are not signaling confidence through purchases. The watch list centers on appeal deadlines (ESS Tech, Outlook Therapeutics) and Leslie's emergence timeline (early 2027).

4 high priority 4 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 30, 2026

The September 30, 2026 filings mark a significant escalation in US retail and pharmaceutical distress, with both Petros Pharmaceuticals and Leslie's, Inc. announcing liquidity events that effectively end or restructure their existing equity structures. Petros Pharmaceuticals executed a General Assignment for the Benefit of Creditors (ABC), a state-law alternative to bankruptcy, resulting in an immediate liquidation event, cessation of operations, and triggering of redemption obligations on preferred stock. Leslie's filed for prearranged Chapter 11 with lender support, aiming to eliminate ~90% of its funded debt ($685M) while securing $150M in new capital and closing 76 stores. Both events are characterized by negative sentiment and maximum materiality, reflecting severe operational and balance sheet stress. The period-over-period data, while not providing specific revenue or margin figures, indicates a complete loss of going concern for Petros and a strategic deleveraging for Leslie's. The market implications are stark: equity holders in both companies face near-total value destruction, while creditors and distressed investors see opportunities in the restructuring. The filings highlight a broader theme of retail and specialty pharmaceutical companies struggling with high leverage and shifting consumer dynamics, leading to insolvency proceedings.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 29, 2026

The four filings in this intelligence stream collectively paint a picture of acute distress across a spectrum of US-listed companies, with a heavy concentration of Nasdaq non-compliance issues. The most critical development is the completed $6.3 billion take-private of Global Business Travel Group (Amex GBT), which, while a positive exit for shareholders, removes a major publicly traded entity and signals a potential trend of private equity scooping up undervalued travel-tech assets. The remaining three filings all involve Nasdaq listing deficiencies, highlighting a systemic stress point for micro-cap and pre-revenue companies. Period-over-period data, where available, shows a clear pattern of deteriorating financial health: SurgePays is fighting a bid price deficiency despite a 180-day extension, while Liminatus Pharma only regained compliance through a dilutive 1-for-50 reverse stock split, a classic sign of financial engineering rather than organic recovery. Maison Solutions is the newest entrant to the distress pool, having failed to file its annual and quarterly reports, suggesting potential accounting or operational issues. The portfolio-level theme is unmistakable: a rising tide of micro-cap companies are failing to meet basic exchange requirements, creating a high-risk environment where delisting and bankruptcy are increasingly probable outcomes for those unable to secure financing or execute a turnaround.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 28, 2026

The two filings in this digest reveal a concentrated micro-cap distress theme within the US small-cap healthcare/consumer staples space, both centered on Nasdaq listing compliance. Hain Celestial Group, a larger branded consumer company, received a transfer to the Nasdaq Capital Market and a 180-day extension to March 22, 2027, to address its bid price deficiency, while simultaneously losing its Chief Accounting Officer—a combination that signals operational and governance strain. Nexalin Technology, a micro-cap medical device maker, faces a more acute crisis with a September 28, 2026 deadline to demonstrate a $1.00 closing bid for 20 consecutive sessions and a January 4, 2027 deadline to restore $2.5M in stockholders' equity, having already received two delisting notices. Both companies exhibit negative sentiment and high materiality (8/10 and 9/10), with no positive period-over-period trends or insider buying to offset the distress. The key differentiator is the timeline: Hain has a longer runway and a more established business, while Nexalin's imminent deadlines create a binary event risk. Neither filing contains revenue, margin, or guidance data, limiting fundamental comparison, but the pattern of repeated compliance failures and executive departures suggests a broader deterioration in small-cap governance and financial health. The market implication is that these are speculative, event-driven situations where the risk of delisting and equity devaluation is elevated, but the potential for a reverse-split-driven rally or a successful equity raise creates short-term trading opportunities.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 25, 2026

This intelligence brief reveals a severe and concentrated wave of corporate distress across US-listed companies, with 8 out of 10 filings detailing active delisting threats or non-compliance with exchange listing standards. The dominant theme is a liquidity and market capitalization crisis, with companies like Silexion, SANUWAVE, Dyadic, and Fusemachines all failing to meet minimum bid price or market value thresholds. The period-over-period data, though limited in this set, points to sustained net losses and equity erosion, as seen in Southland Holdings' $248.2M stockholders' deficit and Calidi Biotherapeutics' sub-$4M equity base. A notable divergence is the voluntary, strategic transfer of Lumen Technologies to Nasdaq, which stands in stark contrast to the involuntary delistings. Insider trading activity is absent across these filings, suggesting a lack of management conviction or an inability to signal confidence. The most critical development is the immediate suspension of SilverBox Corp IV's NYSE trading, forcing it to the OTC market, while the October 2026 compliance plan deadlines for Netcapital, Southland, and Calidi create a high-stakes catalyst calendar. The market implication is clear: investors face a binary risk of total equity loss through forced delistings, with limited recovery prospects for common shareholders.

10 high priority 10 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 24, 2026

The single filing in this digest, from Beasley Broadcast Group Inc., presents a governance-related distress signal rather than a financial or operational crisis. The death of independent director Peter A. Bordes, Jr. has reduced the Audit Committee to two members, triggering non-compliance with Nasdaq's audit committee independence rule. While this is a procedural issue with a cure period extending to September 2027, it introduces near-term uncertainty regarding board composition and regulatory standing. The event is isolated and does not reflect broader sector-wide distress, but it does highlight governance fragility in a small-cap media company. No period-over-period financial trends, insider trading, capital allocation changes, or forward-looking guidance were available in this filing, limiting the depth of quantitative synthesis. The primary actionable insight is the need to monitor the company's ability to appoint a qualified independent director within the cure period, as failure could lead to delisting risk.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 23, 2026

The two filings in this digest both involve Nasdaq delistings, highlighting a concentrated distress pattern among micro-cap healthcare/tech companies facing liquidity and compliance crises. SCWorx Corp. (WORX) and Aditxt, Inc. (ADTX) have both been suspended from Nasdaq and now trade on the OTC markets, with SCWorx attempting a last-minute cure via a private placement and Aditxt facing final delisting. Neither filing provided period-over-period financial comparisons, insider trading data, forward-looking guidance, or capital allocation metrics, limiting quantitative trend analysis. The lack of insider activity and financial metrics in both cases amplifies the opacity and risk, as management has not signaled confidence through purchases or provided turnaround targets. The critical development is SCWorx's October 5, 2026 deadline to regain bid price compliance, which represents a binary catalyst for the stock. The overarching theme is that distressed micro-caps are failing to maintain Nasdaq listing standards post-reverse splits, with no visible insider support or credible recovery plans.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 22, 2026

The single filing in this stream—Reborn Coffee, Inc. (REBN)—presents a severe corporate distress signal, having received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement, reporting only $735,642 as of June 30, 2026. This represents a critical liquidity and solvency event, with the company facing a potential delisting from the Nasdaq Capital Market unless it can submit an acceptable compliance plan by November 2, 2026. The filing's negative sentiment and high materiality score (9/10) underscore the acute risk of bankruptcy or forced restructuring. No period-over-period trends, insider activity, forward-looking guidance, or capital allocation data were available in the enriched analysis, limiting cross-sectional comparisons but highlighting the isolated, binary nature of this distress event. The market implication is clear: REBN is a high-risk name where the equity could be wiped out if the compliance plan fails, making it a pure distress play for speculative investors.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 21, 2026

The September 21, 2026, snapshot reveals a bifurcated distress landscape in the US corporate arena: one company (Linkhome Holdings) successfully resolved its delisting risk by regaining Nasdaq bid price compliance, while another (Sangamo Therapeutics) completed a distressed asset sale post-Chapter 11, resulting in delisting and a transition to the OTC Pink Market. The 50% compliance-to-bankruptcy split within this two-filing sample underscores the binary outcomes inherent in distress situations, with Linkhome demonstrating that proactive balance sheet management can restore listing status, while Sangamo's trajectory highlights the value-destructive path of prolonged insolvency. Notably, neither filing contained period-over-period financial comparisons, insider trading activity, or forward-looking guidance, limiting quantitative trend analysis but emphasizing the event-driven nature of these disclosures. The most material development is Sangamo's $111M upfront asset sale, which, while providing a partial recovery for creditors, marks the end of its operations as a going concern and offers a stark contrast to Linkhome's positive compliance event. The absence of scheduled events in both filings suggests that investors must monitor OTC trading dynamics for Sangamo and ongoing Nasdaq listing standards for Linkhome. Overall, the data points to a market where regulatory compliance events and bankruptcy proceedings are the primary catalysts, with limited forward visibility, making event-driven and post-restructuring analysis critical for investors navigating this distressed landscape.

2 high priority 2 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 21, 2026

This session is exceptionally quiet with only one filing in scope: Sangamo Therapeutics' 8-K confirming the final sale of its ST-920 gene therapy asset to PTC Therapeutics for $111M upfront plus up to $100M in milestones, following its Chapter 11 filing on June 23, 2026. The company's stock was delisted from Nasdaq on September 27, 2026, and now trades on the OTC Pink Market under SGMOQ. This marks the effective end of Sangamo as a going concern, with the bankruptcy process continuing solely for distribution to creditors. There are no period-over-period trends to aggregate across filings, no insider trading activity, no forward-looking guidance, and no capital allocation actions. The sole actionable insight is the confirmation of asset monetization at a material discount, signaling limited recovery for equity holders and a potential template for distressed gene therapy firms.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 18, 2026

The September 18, 2026, batch of US SEC filings is dominated by a wave of micro-cap and small-cap biotech/healthcare companies facing Nasdaq delisting actions, all stemming from sub-$1.00 bid prices or, in one case, insufficient shareholders' equity. 7 of 9 filings are new delisting or going-concern notices, with 6 of those involving minimum bid price deficiencies. This cluster indicates a broad-based liquidity crisis and a potential washout in the speculative biotech sector, likely driven by a prolonged bear market in small-cap healthcare and a lack of risk appetite. The most critical development is the high materiality (8-9/10) of these events, with several companies (Moleculin, NEXTNRG, InMed) facing imminent hearings or having exhausted standard compliance periods. While no period-over-period financial data was provided in these specific filings, the absence of any insider buying to support collapsing stock prices is a notable bearish signal. The primary opportunities lie in event-driven trading around reverse split announcements and potential short squeezes, while the overarching risk is a cascading wave of de-listings that could further depress sentiment in the sector.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 17, 2026

The three filings today paint a stark picture of corporate distress across the US equity markets, with all three companies facing existential threats to their Nasdaq listings. Stardust Power Inc. and Hub Group, Inc. are both at immediate risk of delisting due to non-compliance with listing standards, while CO2 Energy Transition Corp. has been forced to down-list to the Nasdaq Capital Market after its business combination deal fell through. The common thread is a failure to meet basic financial and regulatory requirements, with Hub Group's situation being particularly severe due to its failure to file required periodic reports even after a 180-day extension. The absence of any positive period-over-period trends, insider buying, or capital allocation actions across these filings underscores the depth of their distress. The most critical development is Hub Group's delisting determination, which could trigger a cascade of negative consequences including debt covenant violations and loss of institutional investors. The market implications are clear: investors should avoid these names until concrete turnaround plans are executed, and the broader theme of Nasdaq compliance failures is a red flag for small-cap and micro-cap exposure.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 16, 2026

The September 16, 2026 corporate distress landscape is dominated by a cluster of Nasdaq delisting and non-compliance events, with 4 out of 5 filings directly tied to exchange listing deficiencies. The most severe signal is Synergy CHC Corp's imminent delisting following its Chapter 11 bankruptcy filing, representing a terminal distress event. Aldel Financial II and Bone Biologics are in earlier stages of the compliance process, facing different rule violations (minimum public holders vs. minimum bid price) but sharing a common path of potential delisting if remediation fails. In contrast, Battalion Oil Corp provides a rare positive signal, having successfully regained NYSE American compliance after a multi-quarter turnaround, demonstrating that structured remediation plans can succeed. Exicure, Inc. is on a tight deadline to prove minimum equity compliance by December 2, 2026. A key period-over-period theme is the absence of revenue or margin data in these filings, as they are regulatory 8-Ks focused on listing status; however, the insider trading and forward-looking data within the enriched analysis reveals management's varying levels of conviction, with Bone Biologics actively pursuing a reverse split as a cure, while Synergy CHC's management appears to have abandoned the equity. The overall portfolio-level pattern is a concentration of distress signals in the micro-cap and pre-revenue biotech/SPAC space, where cash burn and low liquidity are chronic risks.

5 high priority 5 total filings